SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-02-03

AUTHORS

Jianfeng Shu, Danrui Cui, Ying Ma, Xiufang Xiong, Yi Sun, Yongchao Zhao

ABSTRACT

Topoisomerase II (TOP2)-targeting anticancer chemotherapeutic drugs, termed TOP2 poisons, are widely used and effective in the clinic by stabilizing TOP2-DNA covalent complexes to induce DNA double-strand breaks (DSBs) and ultimately, cause cell death. The stabilized TOP2-DNA complex is known to be degraded by proteasome, whereas the underlying mechanism for instant TOP2β degradation in response to TOP2 poisons and the subsequent biological consequence remain elusive. Here, we reported that TOP2 poison-induced TOP2β degradation is mediated by SCFβ-TrCP ubiquitin ligase. Specifically, DNA damage signal, triggered by teniposide (VM-26) treatment, activates ATM, cooperating with CK1 to phosphorylate TOP2β on Ser1134 and Ser1130, respectively, in a canonical degron motif to facilitate β-TrCP binding and subsequent degradation. Inactivation of ATM, CK1 or SCFβ-TrCP by small molecular inhibitors or genetic knockdown/knockout abrogates TOP2β degradation. Biologically, blockage of TOP2β degradation in combination with VM-26 treatment impairs DNA damage response and repair, leading to an accelerated cell death via apoptosis. Thus, it appears that TOP2β degradation is a cellular defensive mechanism to facilitate the exposure of DSBs to trigger DNA damage response and repair. Collectively, our findings reveal a new strategy to improve the efficacy of TOP2 poisons in combination with small-molecule inhibitors against TOP2β degradation. More... »

PAGES

8

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41389-020-0196-1

DOI

http://dx.doi.org/10.1038/s41389-020-0196-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1124547386

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32015321


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shu", 
        "givenName": "Jianfeng", 
        "id": "sg:person.013676661257.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676661257.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cui", 
        "givenName": "Danrui", 
        "id": "sg:person.0732121253.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732121253.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ma", 
        "givenName": "Ying", 
        "id": "sg:person.010025231023.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025231023.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
            "Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Xiufang", 
        "id": "sg:person.01110467571.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110467571.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
            "Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sun", 
        "givenName": "Yi", 
        "id": "sg:person.0653315700.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653315700.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China", 
            "Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Yongchao", 
        "id": "sg:person.01304472406.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304472406.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41418-019-0402-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1120290071", 
          "https://doi.org/10.1038/s41418-019-0402-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2396", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035090349", 
          "https://doi.org/10.1038/nrc2396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009347977", 
          "https://doi.org/10.1038/nm.2919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nprot.2006.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004995401", 
          "https://doi.org/10.1038/nprot.2006.5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036271660", 
          "https://doi.org/10.1038/nrc2608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncb2463", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008291515", 
          "https://doi.org/10.1038/ncb2463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042974714", 
          "https://doi.org/10.1038/nrc2607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2013.201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032572342", 
          "https://doi.org/10.1038/clpt.2013.201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3700", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020362180", 
          "https://doi.org/10.1038/nrc3700"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-02-03", 
    "datePublishedReg": "2020-02-03", 
    "description": "Topoisomerase II (TOP2)-targeting anticancer chemotherapeutic drugs, termed TOP2 poisons, are widely used and effective in the clinic by stabilizing TOP2-DNA covalent complexes to induce DNA double-strand breaks (DSBs) and ultimately, cause cell death. The stabilized TOP2-DNA complex is known to be degraded by proteasome, whereas the underlying mechanism for instant TOP2\u03b2 degradation in response to TOP2 poisons and the subsequent biological consequence remain elusive. Here, we reported that TOP2 poison-induced TOP2\u03b2 degradation is mediated by SCF\u03b2-TrCP ubiquitin ligase. Specifically, DNA damage signal, triggered by teniposide (VM-26) treatment, activates ATM, cooperating with CK1 to phosphorylate TOP2\u03b2 on Ser1134 and Ser1130, respectively, in a canonical degron motif to facilitate \u03b2-TrCP binding and subsequent degradation. Inactivation of ATM, CK1 or SCF\u03b2-TrCP by small molecular inhibitors or genetic knockdown/knockout abrogates TOP2\u03b2 degradation. Biologically, blockage of TOP2\u03b2 degradation in combination with VM-26 treatment impairs DNA damage response and repair, leading to an accelerated cell death via apoptosis. Thus, it appears that TOP2\u03b2 degradation is a cellular defensive mechanism to facilitate the exposure of DSBs to trigger DNA damage response and repair. Collectively, our findings reveal a new strategy to improve the efficacy of TOP2 poisons in combination with small-molecule inhibitors against TOP2\u03b2 degradation.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41389-020-0196-1", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8187234", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8184491", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8366544", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8356972", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8351554", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8360856", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8889183", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8351544", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1046557", 
        "issn": [
          "2157-9024"
        ], 
        "name": "Oncogenesis", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "DNA double-strand breaks", 
      "DNA damage response", 
      "TOP2 poisons", 
      "damage response", 
      "TOP2-DNA covalent complexes", 
      "impairs DNA damage response", 
      "\u03b2-TrCP binding", 
      "cell death", 
      "DNA damage signals", 
      "subsequent biological consequences", 
      "TOP2-DNA complexes", 
      "topoisomerase II", 
      "inactivation of ATM", 
      "knockdown/knockout", 
      "double-strand breaks", 
      "accelerated cell death", 
      "cellular defensive mechanisms", 
      "cancer cell survival", 
      "small molecular inhibitors", 
      "small molecule inhibitors", 
      "degron motif", 
      "damage signals", 
      "biological consequences", 
      "cell survival", 
      "subsequent degradation", 
      "molecular inhibitors", 
      "covalent complex", 
      "teniposide treatment", 
      "chemotherapeutic drugs", 
      "TOP2\u03b2", 
      "defensive mechanisms", 
      "CK1", 
      "anticancer chemotherapeutic drugs", 
      "underlying mechanism", 
      "degradation", 
      "ubiquitin", 
      "proteasome", 
      "inhibitors", 
      "complexes", 
      "motif", 
      "knockout", 
      "apoptosis", 
      "mechanism", 
      "repair", 
      "poisons", 
      "binding", 
      "inactivation", 
      "response", 
      "new strategy", 
      "atm", 
      "death", 
      "breaks", 
      "survival", 
      "combination", 
      "signals", 
      "blockage", 
      "consequences", 
      "exposure", 
      "drugs", 
      "strategies", 
      "findings", 
      "treatment", 
      "efficacy", 
      "clinic"
    ], 
    "name": "SCF\u03b2-TrCP-mediated degradation of TOP2\u03b2 promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II", 
    "pagination": "8", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1124547386"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41389-020-0196-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32015321"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41389-020-0196-1", 
      "https://app.dimensions.ai/details/publication/pub.1124547386"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_858.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41389-020-0196-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41389-020-0196-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41389-020-0196-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41389-020-0196-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41389-020-0196-1'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      21 PREDICATES      98 URIs      81 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41389-020-0196-1 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N0c9b352846024d4f8180d8abc73e4306
4 schema:citation sg:pub.10.1038/clpt.2013.201
5 sg:pub.10.1038/ncb2463
6 sg:pub.10.1038/nm.2919
7 sg:pub.10.1038/nprot.2006.5
8 sg:pub.10.1038/nrc2396
9 sg:pub.10.1038/nrc2607
10 sg:pub.10.1038/nrc2608
11 sg:pub.10.1038/nrc3700
12 sg:pub.10.1038/s41418-019-0402-x
13 schema:datePublished 2020-02-03
14 schema:datePublishedReg 2020-02-03
15 schema:description Topoisomerase II (TOP2)-targeting anticancer chemotherapeutic drugs, termed TOP2 poisons, are widely used and effective in the clinic by stabilizing TOP2-DNA covalent complexes to induce DNA double-strand breaks (DSBs) and ultimately, cause cell death. The stabilized TOP2-DNA complex is known to be degraded by proteasome, whereas the underlying mechanism for instant TOP2β degradation in response to TOP2 poisons and the subsequent biological consequence remain elusive. Here, we reported that TOP2 poison-induced TOP2β degradation is mediated by SCFβ-TrCP ubiquitin ligase. Specifically, DNA damage signal, triggered by teniposide (VM-26) treatment, activates ATM, cooperating with CK1 to phosphorylate TOP2β on Ser1134 and Ser1130, respectively, in a canonical degron motif to facilitate β-TrCP binding and subsequent degradation. Inactivation of ATM, CK1 or SCFβ-TrCP by small molecular inhibitors or genetic knockdown/knockout abrogates TOP2β degradation. Biologically, blockage of TOP2β degradation in combination with VM-26 treatment impairs DNA damage response and repair, leading to an accelerated cell death via apoptosis. Thus, it appears that TOP2β degradation is a cellular defensive mechanism to facilitate the exposure of DSBs to trigger DNA damage response and repair. Collectively, our findings reveal a new strategy to improve the efficacy of TOP2 poisons in combination with small-molecule inhibitors against TOP2β degradation.
16 schema:genre article
17 schema:isAccessibleForFree true
18 schema:isPartOf N970ad33a7ee84cb5ae9a32218bb8287b
19 Nad19253d159f4463a213db875965f741
20 sg:journal.1046557
21 schema:keywords CK1
22 DNA damage response
23 DNA damage signals
24 DNA double-strand breaks
25 TOP2 poisons
26 TOP2-DNA complexes
27 TOP2-DNA covalent complexes
28 TOP2β
29 accelerated cell death
30 anticancer chemotherapeutic drugs
31 apoptosis
32 atm
33 binding
34 biological consequences
35 blockage
36 breaks
37 cancer cell survival
38 cell death
39 cell survival
40 cellular defensive mechanisms
41 chemotherapeutic drugs
42 clinic
43 combination
44 complexes
45 consequences
46 covalent complex
47 damage response
48 damage signals
49 death
50 defensive mechanisms
51 degradation
52 degron motif
53 double-strand breaks
54 drugs
55 efficacy
56 exposure
57 findings
58 impairs DNA damage response
59 inactivation
60 inactivation of ATM
61 inhibitors
62 knockdown/knockout
63 knockout
64 mechanism
65 molecular inhibitors
66 motif
67 new strategy
68 poisons
69 proteasome
70 repair
71 response
72 signals
73 small molecular inhibitors
74 small molecule inhibitors
75 strategies
76 subsequent biological consequences
77 subsequent degradation
78 survival
79 teniposide treatment
80 topoisomerase II
81 treatment
82 ubiquitin
83 underlying mechanism
84 β-TrCP binding
85 schema:name SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II
86 schema:pagination 8
87 schema:productId N2eb3d93a8dd74c70a5a65beb18f342e7
88 Ncc819b9c24c6441b86a644c517b16c5f
89 Nd7637bf7af784737bffc8a2f94af014b
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124547386
91 https://doi.org/10.1038/s41389-020-0196-1
92 schema:sdDatePublished 2022-10-01T06:47
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nc7014e1c958a4f73ab57e94f5704502b
95 schema:url https://doi.org/10.1038/s41389-020-0196-1
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N0c9b352846024d4f8180d8abc73e4306 rdf:first sg:person.013676661257.35
100 rdf:rest N36ccf8def4ed441c95abaa27905fdc19
101 N2eb3d93a8dd74c70a5a65beb18f342e7 schema:name doi
102 schema:value 10.1038/s41389-020-0196-1
103 rdf:type schema:PropertyValue
104 N36ccf8def4ed441c95abaa27905fdc19 rdf:first sg:person.0732121253.08
105 rdf:rest N5adc19a430ed49c78ee7e6e0d6999fc5
106 N37b3376708d54fe39d458b63f4da4530 rdf:first sg:person.0653315700.70
107 rdf:rest N58a2738d2e964c6097dc17c77056f9cc
108 N58a2738d2e964c6097dc17c77056f9cc rdf:first sg:person.01304472406.33
109 rdf:rest rdf:nil
110 N5adc19a430ed49c78ee7e6e0d6999fc5 rdf:first sg:person.010025231023.36
111 rdf:rest N6c8c64ac4c1e4affa2daf4dc8a51f228
112 N6c8c64ac4c1e4affa2daf4dc8a51f228 rdf:first sg:person.01110467571.75
113 rdf:rest N37b3376708d54fe39d458b63f4da4530
114 N970ad33a7ee84cb5ae9a32218bb8287b schema:volumeNumber 9
115 rdf:type schema:PublicationVolume
116 Nad19253d159f4463a213db875965f741 schema:issueNumber 2
117 rdf:type schema:PublicationIssue
118 Nc7014e1c958a4f73ab57e94f5704502b schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Ncc819b9c24c6441b86a644c517b16c5f schema:name pubmed_id
121 schema:value 32015321
122 rdf:type schema:PropertyValue
123 Nd7637bf7af784737bffc8a2f94af014b schema:name dimensions_id
124 schema:value pub.1124547386
125 rdf:type schema:PropertyValue
126 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
127 schema:name Biological Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
130 schema:name Biochemistry and Cell Biology
131 rdf:type schema:DefinedTerm
132 sg:grant.8184491 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
133 rdf:type schema:MonetaryGrant
134 sg:grant.8187234 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
135 rdf:type schema:MonetaryGrant
136 sg:grant.8351544 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
137 rdf:type schema:MonetaryGrant
138 sg:grant.8351554 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
139 rdf:type schema:MonetaryGrant
140 sg:grant.8356972 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
141 rdf:type schema:MonetaryGrant
142 sg:grant.8360856 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
143 rdf:type schema:MonetaryGrant
144 sg:grant.8366544 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
145 rdf:type schema:MonetaryGrant
146 sg:grant.8889183 http://pending.schema.org/fundedItem sg:pub.10.1038/s41389-020-0196-1
147 rdf:type schema:MonetaryGrant
148 sg:journal.1046557 schema:issn 2157-9024
149 schema:name Oncogenesis
150 schema:publisher Springer Nature
151 rdf:type schema:Periodical
152 sg:person.010025231023.36 schema:affiliation grid-institutes:grid.13402.34
153 schema:familyName Ma
154 schema:givenName Ying
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025231023.36
156 rdf:type schema:Person
157 sg:person.01110467571.75 schema:affiliation grid-institutes:grid.13402.34
158 schema:familyName Xiong
159 schema:givenName Xiufang
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110467571.75
161 rdf:type schema:Person
162 sg:person.01304472406.33 schema:affiliation grid-institutes:grid.13402.34
163 schema:familyName Zhao
164 schema:givenName Yongchao
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304472406.33
166 rdf:type schema:Person
167 sg:person.013676661257.35 schema:affiliation grid-institutes:grid.13402.34
168 schema:familyName Shu
169 schema:givenName Jianfeng
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676661257.35
171 rdf:type schema:Person
172 sg:person.0653315700.70 schema:affiliation grid-institutes:grid.13402.34
173 schema:familyName Sun
174 schema:givenName Yi
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653315700.70
176 rdf:type schema:Person
177 sg:person.0732121253.08 schema:affiliation grid-institutes:grid.13402.34
178 schema:familyName Cui
179 schema:givenName Danrui
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732121253.08
181 rdf:type schema:Person
182 sg:pub.10.1038/clpt.2013.201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032572342
183 https://doi.org/10.1038/clpt.2013.201
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/ncb2463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008291515
186 https://doi.org/10.1038/ncb2463
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/nm.2919 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009347977
189 https://doi.org/10.1038/nm.2919
190 rdf:type schema:CreativeWork
191 sg:pub.10.1038/nprot.2006.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004995401
192 https://doi.org/10.1038/nprot.2006.5
193 rdf:type schema:CreativeWork
194 sg:pub.10.1038/nrc2396 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035090349
195 https://doi.org/10.1038/nrc2396
196 rdf:type schema:CreativeWork
197 sg:pub.10.1038/nrc2607 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042974714
198 https://doi.org/10.1038/nrc2607
199 rdf:type schema:CreativeWork
200 sg:pub.10.1038/nrc2608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036271660
201 https://doi.org/10.1038/nrc2608
202 rdf:type schema:CreativeWork
203 sg:pub.10.1038/nrc3700 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020362180
204 https://doi.org/10.1038/nrc3700
205 rdf:type schema:CreativeWork
206 sg:pub.10.1038/s41418-019-0402-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1120290071
207 https://doi.org/10.1038/s41418-019-0402-x
208 rdf:type schema:CreativeWork
209 grid-institutes:grid.13402.34 schema:alternateName Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
210 Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
211 schema:name Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
212 Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
213 Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...